No Brexit for rare disease patients
Tuesday 24 January 2017, RPP Healthcare collaborated with patients and MEPs in hosting a European Parliament event to debate crucial healthcare issues in the upcoming Brexit negotiations. With numerous UK and non-UK MEPs supporting this initiative, the participants discussed the crucial EU added value for rare disease patients and research.
On the day that the Supreme Court ruled in favour of Parliamentary vote on this topic, the event offered a timely opportunity to project the voice of the rare disease community.
RPP will continue to collaborate with patients, researchers and MEPs to deliver recommendations to UK policy makers on the needs of patients and researchers in Brexit negotiations. Participants were keen to ensure patients are not left behind and our work will be towards ensuring a positive outcome for patients in the UK and across the EU.